[Progress in the field of drug development. 8].
D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000701:Analgesics, Opioid; D000777:Anesthetics; D000818:Animals; D000889:Anti-Arrhythmia Agents; D000893:Anti-Inflammatory Agents; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D000996:Antitussive Agents; D006634:Histamine H1 Antagonists; D006801:Humans; D006993:Hypnotics and Sedatives; D000960:Hypolipidemic Agents; D009125:Muscle Relaxants, Central; D010276:Parasympatholytics; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis*; D014665:Vasodilator Agents
D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000701:Analgesics, Opioid; D000777:Anesthetics; D000889:Anti-Arrhythmia Agents; D000893:Anti-Inflammatory Agents; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D000996:Antitussive Agents; D006634:Histamine H1 Antagonists; D006993:Hypnotics and Sedatives; D000960:Hypolipidemic Agents; D009125:Muscle Relaxants, Central; D010276:Parasympatholytics; D004364:Pharmaceutical Preparations; D014665:Vasodilator Agents
Fortschritte auf dem Gebiet der Arzneimittelentwicklung. Teil 8